LogicBio Therapeutics Stock Forecast, Price & News

-0.13 (-3.16 %)
(As of 06/18/2021 10:40 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,326 shs
Average Volume144,943 shs
Market Capitalization$128.00 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LogicBio Therapeutics logo

About LogicBio Therapeutics

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.35 out of 5 stars

Medical Sector

813th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

119th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

Is LogicBio Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LogicBio Therapeutics stock.
View analyst ratings for LogicBio Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than LogicBio Therapeutics?

Wall Street analysts have given LogicBio Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but LogicBio Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for LogicBio Therapeutics

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its quarterly earnings results on Monday, May, 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.06. The business earned $0.46 million during the quarter.
View LogicBio Therapeutics' earnings history

How has LogicBio Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LOGC stock has decreased by 43.5% and is now trading at $3.98.
View which stocks have been most impacted by COVID-19

What price target have analysts set for LOGC?

4 brokerages have issued twelve-month price objectives for LogicBio Therapeutics' stock. Their forecasts range from $15.00 to $20.00. On average, they expect LogicBio Therapeutics' stock price to reach $17.33 in the next year. This suggests a possible upside of 335.5% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau M.B.A., Pres, CEO & Director (Age 54, Pay $677.2k)
  • Dr. Mark A. Kay, Co-Founder & Independent Director (Age 63, Pay $85k)
  • Dr. Kyle Chiang Ph.D., Chief Operating Officer (Age 41, Pay $348.85k)
  • Ms. Mariana Nacht, Chief Scientific Officer (Age 57, Pay $429.64k)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel Ph.D., Co-Founder
  • Ms. Cecilia Jones, Chief Financial Officer (Age 46)
  • Dr. Matthias Hebben, Global VP & Head of Technology Devel.
  • Mr. Matthias B. Jaffe, Consultant (Age 52)
  • Dr. Daniel J. Gruskin M.D., Sr. VP & Head of Clinical Devel.

Who are some of LogicBio Therapeutics' key competitors?

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

Who are LogicBio Therapeutics' major shareholders?

LogicBio Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Samlyn Capital LLC (4.35%), BlackRock Inc. (3.06%), EcoR1 Capital LLC (2.14%), Pura Vida Investments LLC (0.79%), JPMorgan Chase & Co. (0.75%) and Geode Capital Management LLC (0.71%). Company insiders that own LogicBio Therapeutics stock include Bioscience Plc Arix, Frederic Chereau, Kyle Chiang and Orbimed Advisors Llc.
View institutional ownership trends for LogicBio Therapeutics

Which major investors are selling LogicBio Therapeutics stock?

LOGC stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, JPMorgan Chase & Co., Samlyn Capital LLC, Morgan Stanley, Northern Trust Corp, and Verition Fund Management LLC. Company insiders that have sold LogicBio Therapeutics company stock in the last year include Bioscience Plc Arix, Frederic Chereau, and Kyle Chiang.
View insider buying and selling activity for LogicBio Therapeutics
or view top insider-selling stocks.

Which major investors are buying LogicBio Therapeutics stock?

LOGC stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, BlackRock Inc., Geode Capital Management LLC, Virtu Financial LLC, Trexquant Investment LP, Squarepoint Ops LLC, Texas Yale Capital Corp., and Barclays PLC.
View insider buying and selling activity for LogicBio Therapeutics
or or view top insider-buying stocks.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $3.98.

How much money does LogicBio Therapeutics make?

LogicBio Therapeutics has a market capitalization of $128.00 million and generates $3.45 million in revenue each year. The company earns $-32,620,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How many employees does LogicBio Therapeutics have?

LogicBio Therapeutics employs 39 workers across the globe.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is

Where are LogicBio Therapeutics' headquarters?

LogicBio Therapeutics is headquartered at 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.